Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
about
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cellsThe long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.
P2860
Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Imatinib mesylate as treatment ...... chronic myelogenous leukemia.
@ast
Imatinib mesylate as treatment ...... chronic myelogenous leukemia.
@en
type
label
Imatinib mesylate as treatment ...... chronic myelogenous leukemia.
@ast
Imatinib mesylate as treatment ...... chronic myelogenous leukemia.
@en
prefLabel
Imatinib mesylate as treatment ...... chronic myelogenous leukemia.
@ast
Imatinib mesylate as treatment ...... chronic myelogenous leukemia.
@en
P2093
P1433
P1476
Imatinib mesylate as treatment ...... e chronic myelogenous leukemia
@en
P2093
Anna Sureda
Eulogio Conde
Jesùs A Martínez
Joaquin Díaz-Mediavilla
Jorge Sierra
Marina Carrasco
Miguel de Miguel
P304
P577
2003-11-01T00:00:00Z